Roth Capital Issues Negative Outlook for CervoMed Earnings

CervoMed Inc. (NASDAQ:CRVO) – Investment analysts at Roth Capital dropped their Q1 2025 earnings per share (EPS) estimates for shares of CervoMed in a report issued on Tuesday, March 18th. Roth Capital analyst B. Pachaiyappan now expects that the company will post earnings of ($0.80) per share for the quarter, down from their prior forecast of ($0.52). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed’s Q2 2025 earnings at ($0.73) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($2.47) EPS.

CervoMed (NASDAQ:CRVO) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%. The business had revenue of $2.16 million during the quarter, compared to analyst estimates of $1.51 million.

A number of other research analysts also recently weighed in on CRVO. Brookline Capital Management raised CervoMed from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 11th. Roth Mkm upped their price target on CervoMed from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of CervoMed in a research note on Monday. Morgan Stanley reaffirmed an “underweight” rating on shares of CervoMed in a research note on Wednesday, December 11th. Finally, Canaccord Genuity Group upped their price target on CervoMed from $12.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

CervoMed Stock Up 0.3 %

CRVO stock opened at $9.37 on Thursday. The stock’s 50 day simple moving average is $2.87 and its 200 day simple moving average is $7.88. CervoMed has a fifty-two week low of $1.80 and a fifty-two week high of $26.38.

Hedge Funds Weigh In On CervoMed

Institutional investors and hedge funds have recently bought and sold shares of the company. Virtu Financial LLC bought a new position in CervoMed during the fourth quarter valued at $26,000. DRW Securities LLC bought a new position in CervoMed during the fourth quarter valued at $30,000. Mariner LLC bought a new position in CervoMed during the fourth quarter valued at $30,000. BNP Paribas Financial Markets bought a new position in CervoMed during the fourth quarter valued at $32,000. Finally, JPMorgan Chase & Co. grew its holdings in CervoMed by 251.8% during the fourth quarter. JPMorgan Chase & Co. now owns 14,464 shares of the company’s stock valued at $34,000 after purchasing an additional 10,352 shares during the period. 25.15% of the stock is owned by institutional investors.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.